Skadden presented a seminar on September 12 titled "Decoupling a Biotech/Pharma Alliance: How Amylin Pharmaceuticals Unlocked Value by Challenging Its Partnership With Eli Lilly & Co., Paving the Way for Its Multibillion Dollar Acquisition by Bristol-Myers Squibb." Held in the firm's Boston office, the seminar provided a first-hand account of how Amylin successfully terminated its decade-long alliance with Eli Lilly and reacquired the worldwide development and commercialization rights to its leading diabetes drug exenatide in a deal worth up to $1.6 billion in 2011. With increased flexibility and a blockbuster new product with FDA marketing clearance, Amylin was acquired subsequently in 2012 by Bristol-Myers Squibb for $7 billion, which included resolving multiple lawsuits brought by activist shareholders, such as Carl Icahn. The seminar was moderated by Boston corporate partner Graham Robinson and included as speakers New York M&A partner Nancy Lieberman and litigation partner Maura Barry Grinalds, as well as Marcea Bland Lloyd, Amylin's former senior vice president, chief administrative officer and general counsel.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates